Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BEAT
BEAT logo

BEAT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Heartbeam Inc (BEAT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.220
1 Day change
8.93%
52 Week Range
4.000
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Heartbeam Inc (BEAT) is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, the financial performance shows no revenue growth with increasing losses, and there are no positive catalysts or significant trading trends to suggest an upward trajectory. Additionally, there are no recent AI Stock Picker or SwingMax signals to support a buy decision.

Technical Analysis

The technical indicators are bearish. The MACD is negative and expanding downward, the RSI is neutral but close to oversold levels, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 1.113 and S2 at 1.031.

Positive Catalysts

  • NULL identified. No recent news, trading trends, or positive financial developments.

Neutral/Negative Catalysts

  • Bearish technical indicators, declining EPS (-16.67% YoY), and no revenue growth. The stock is also underperforming the broader market, which is down 1.79%.

Financial Performance

In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of -$5.3M (improved by 8.05% YoY), and a decline in EPS to -0.15 (-16.67% YoY). Gross margin remains at 0%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast BEAT stock price to rise
3 Analyst Rating
Wall Street analysts forecast BEAT stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.120
sliders
Low
4
Averages
5.83
High
8
Current: 1.120
sliders
Low
4
Averages
5.83
High
8
Stifel
initiated
$4
AI Analysis
2026-03-31
New
Reason
Stifel
Price Target
$4
AI Analysis
2026-03-31
New
initiated
Reason
Stifel initiated coverage of HeartBeam with a Buy rating and $4 price target. HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free device capable of synthesizing a clinical-grade 12-lead electrocardiogram from 3D signal capture, the analyst tells investors in a research note. The firm expects "rapid deployment" of HeartBeam Systems across concierge and preventive cardiology practices. Riley expects positive stock momentum to build with the company's regulatory updates from expansion over the coming years.
B. Riley
B. Riley
initiated
$4
2026-03-31
New
Reason
B. Riley
B. Riley
Price Target
$4
2026-03-31
New
initiated
Reason
B. Riley initiated coverage of HeartBeam with a Buy rating and $4 price target. HeartBeam is a medical technology company that has developed the first and only FDA-cleared, cable-free device capable of synthesizing a clinical-grade 12-lead electrocardiogram from 3D signal capture, the analyst tells investors in a research note. The firm expects "rapid deployment" of HeartBeam Systems across concierge and preventive cardiology practices. Riley expects positive stock momentum to build with the company's regulatory updates from expansion over the coming years.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BEAT
Unlock Now

People Also Watch